Tag: MDVN
Buy These 3 Takeover Targets For 2016
In my last column, I spoke on how M&A chatter has been increasing in the small and mid-cap names within the biotech sector. The derailment of the huge $150 billion merger between Pfizer (NYSE: PFE) and Allergan (NYSE: AGN) is leading many analysts to put forth a list of names these companies could target as they […]
